home > news > detailed info

PCI Pharma Services Appoints New Chief Financial Officer SVP Serge Dupuis

PCI Pharma Services

Philadelphia, PA – 22 March, 2019. Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to welcome Serge Dupuis as Senior Vice President and Chief Financial Officer (CFO).

Serge’s appointment supports PCI’s continued strategic growth and expansion across its global network, currently spanning 20 facilities in eight locations across three continents. PCI features a broad portfolio of outsourced development and commercialization services focused in drug development and manufacturing, clinical trial supply, as well as commercial contract packaging.

Serge brings to PCI more than 20 years’ experience in senior leadership roles, mainly in manufacturing environments. He joins the organization from CSP Technologies where he held the role of CFO. Prior to this, Serge served in significant senior-level roles with a range of internationally-recognized manufacturing and services, logistics and defense companies.

In welcoming Serge to PCI, Chief Executive Officer Salim Haffar said: “We are delighted Serge is joining us during this transformative time in PCI’s growth. His appointment is significant; confirming our long-standing commitment to partnering with leading pharmaceutical and biotech companies and help bring their life-saving medicines to patients around the world. Our trusted relationships with our customers are at the heart of all we do; our strategic growth plan, backed by robust global investment, reflects this. Serge will play an invaluable role as we build new capabilities and capacity, supported by innovative technology and first-class equipment – ensuring PCI continues to deliver outstanding quality and service for our clients in both established and emerging global markets.”

Serge added: “I am excited to join the PCI organization, a very successful and unique leader in the pharmaceutical and biotech industry. I believe that PCI is very well-positioned and has a tremendous growth potential based on the impressive reputation, depth of knowledge and sizeable investment.”

PCI recently expanded operations through acquisition, adding key locations in San Diego, Dublin and Melbourne, as well as announcing a record year for capital investment across its global business.

For more information, please visit

About PCI Pharma Services
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enables us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives. For more information, please visit or follow us on Twitter at @PCI_Social.

Tom Gosschalk / Carrie Lowe at BECG

T: +44 (0)20 3697 7647 / +44 (0)1962 893 913
phone +44 (0)1495 713 633
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
Print this page
Send to a friend
News and Press Releases

WuXi STA and Dizal Pharmaceutical Sign CMC Development and Manufacturing Agreement

STA Pharmaceutical Co., Ltd., (WuXi STA) – a subsidiary of WuXi AppTec – and Dizal Pharmaceutical, a biotechnology company, announce a strategic partnership. Under the terms of the collaboration, WuXi STA will become the preferred CDMO partner of Dizal Pharmaceutical for GMP production, providing integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services from API to drug product.
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?


Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

Industry Events

CPhI Korea

21-23 August 2019, COEX, Seoul, South Korea

CPhI Korea provides a dynamic meeting place for a wide range of industry suppliers to engage with purchasers and decision makers from the pharmaceutical industry in Korea and the surrounding region. The exhibition showcases the whole pharma supply chain from ingredients, contracting services to machinery and biopharmaceuticals. It also hosts an extensive conference programme covering the latest trends and topics within the regional market.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement